ImmunoGenesis Doses First Patient in Clinical Trial of Drug for Advanced Solid Tumors
The drug is the first that targets two antibodies with cytotoxic function designed to treat cancers that are resistant to existing immunotherapies
Cancer Focus Fund Investing $4.5 Million in ImmunoGenesis to Support Drug Trial for Relapsed or Refractory Advanced Solid Tumors
ImmunoGenesis’ drug is a dual-specific antibody designed to treat tumors that are resistant to existing immunotherapy. CFF's investment will support a multi-site clinical trial of the drug being conducted at MD Anderson.